Dual Therapy With SGLT2 and GLP-1 Shows Reductions in Risk of Colon Cancer for Patients With Diabetes

For pharmacists managing the complex needs of patients with type 2 diabetes (T2D), a growing body of evidence suggests that the choice of glucose-lowering therapy may play a critical role in colorectal cancer prevention. A trial emulation published in Diabetology and Metabolic Syndrome reveals that dual therapy combining sodium-glucose cotransporter-2 (SGLT2) inhibitors with glucagon-like peptide-1 (GLP-1) receptor agonists is associated with a 21% lower risk of colon cancer in high-risk patients with a history of polypectomy. This finding, derived from a large-scale analysis of over 57,000 patients, suggests that the combination of these 2 drug classes may offer additive chemopreventive effects that surpass the benefits of monotherapy alone.¹

“Despite the established individual anticancer potential of both drug classes, no study has investigated whether dual SGLT2 inhibitor plus GLP-1 RA therapy confers additional protection against colon cancer beyond either agent alone,” the study author said. “We therefore conducted this target trial emulation study to compare colon cancer risk between patients receiving dual therapy versus SGLT2 inhibitor monotherapy among post-polypectomy patients with T2DM.”

The study, which utilized the TriNetX Global Collaborative Network to compare dual therapy against SGLT2 inhibitor monotherapy, found that the protective association extended beyond just colon cancer. Patients on the combination regimen also demonstrated significant reductions in other gastrointestinal cancers, colectomy rates, and all-cause mortality. For pharmacists, these results are particularly relevant when counseling patients who already face an elevated baseline risk of colorectal malignancy due to both their diabetic status and prior history of colonic polyps.

The broader clinical context supports the potential of GLP-1 receptor agonists in reducing cancer risk, though the landscape remains nuanced. Earlier research published in JAMA Oncology indicated that GLP-1 receptor agonists were associated with a decreased risk of colorectal cancer compared to traditional treatments like insulin and metformin, with the most profound protective effects observed in patients with obesity or overweight. This suggests that the weight-loss properties and anti-inflammatory effects of these medications may be partially responsible for their oncological benefits.^2,3

However, pharmacists must balance these protective findings with a critical risk signal emerging from recent network meta-analyses. Although the GLP-1 class generally appears beneficial, a comprehensive analysis of 68 randomized controlled trials found that semaglutide, specifically in its high-dose injectable form of 2.4 mg per week, was associated with a 49% increased incidence of colorectal tumors compared to controls. This discrepancy suggests that though most agents in these classes may be protective, semaglutide might be an outlier due to its specific pharmacokinetic properties or its potential to stimulate certain proliferative pathways.³

The theoretical mechanisms behind these findings involve the activation of various signaling pathways. Although some therapies may reduce cancer risk by lowering insulin levels and decreasing inflammation, semaglutide has been noted for its potential anti-apoptotic effects via the activation of protein kinase C-epsilon and the ERK1/2-MAPK pathway, which are frequently dysregulated in colorectal tumors. Its molecular structure also allows for a longer presence in the blood, potentially leading to sustained stimulation of intestinal growth pathways.³

“To our knowledge, this is the first study to evaluate the association of dual SGLT2 inhibitor plus GLP-1 RA therapy with colon cancer risk, and the first study to examine antidiabetic medications specifically in a post-polypectomy population,” the study authors said.¹ “Prior studies examining individual agents reported SGLT2 inhibitor monotherapy to be associated with a 20–29% reduction in CRC risk versus other antidiabetic agents, and GLP-1 RA monotherapy to be associated with a 23–30% reduction.”

For the pharmacy profession, these findings emphasize the importance of personalized medicine in diabetes management. When evaluating patients with a high risk for colorectal cancer, such as those with a history of polyps, the additive benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists appear significant, but the specific choice of agent and dosage may require careful consideration. Although dual therapy has shown clear potential for chemoprevention in post-polypectomy patients, the dose-dependent risk signal associated with high-dose semaglutide warrants cautious monitoring and further prospective investigation to ensure patient safety across all populations.^1,3

READ MORE: Diabetes Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Wang CH, Chang WC, Chen HY, Chen PH, Lin MH, Lee CH. Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation. Diabetol Metab Syndr. Published online March 29, 2026. doi:10.1186/s13098-026-02151-x

2. Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA Oncol. 2024;10(2):256-258. doi:10.1001/jamaoncol.2023.5573

3. Hung CM, Zeng BY, Hsu CW, et al. The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials. Int J Surg. 2026;112(1):443-459. doi:10.1097/JS9.0000000000003450